A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells

Biomedicine and Pharmacotherapy

Volumn 67, Issue 5, 2013, Pages 407-415

  Patra, Nabanita ^a   De, Umasankar ^a   Kim, Tae Hyung ^a   Lee, Young Ju ^a   Ahn, Mee Young ^a   Kim, Nam Deuk ^a   Yoon, Jung Hyun ^a   Choi, Wahn Soo ^b   Moon, Hyung Ryong ^a   Lee, Byung Mu ^c   Kim, Hyung Sik ^c  

^a Pusan National University   (South Korea)

^b Konkuk University School of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Apoptosis; Cell cycle; HDAC inhibitor; MHY219; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CYCLIN B1; CYCLIN D1; HISTONE DEACETYLASE INHIBITOR; MHY 219; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL STRAIN LNCAP; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; FLOW CYTOMETRY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIPHENYLAMINE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; MALE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; UP-REGULATION;

EID: 84878372331     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.01.006     Document Type: Article

References (47)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Prins G.S. Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 2008, 15:649-656.
3. Catalona W.J. Management of cancer of the prostate. N Engl J Med 1994, 331:996-1004.
4. Dowling A.J., Tannock I.F. Systemic treatment for prostate cancer. Cancer Treat Rev 1998, 24:283-301.
5. Debicki S., Jagodzinski P.P. Apicidin decreases phospholipase C gamma-1 transcript and protein in Hut-78 T lymphoma cells. Biomed Pharmacother 2009, 63:543-547.
6. Łuczak M.W., Jagodziński P.P. Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells. Biomed Pharmacother 2009, 63:262-266.
7. Patra S.K., Patra A., Dahiya R. Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 2001, 287:705-713.
8. Halkidou K., Cook S., Leung H.Y., Neal D.E., Robson C.N. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol 2004, 45:382-389.
9. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
10. Robbins A.R., Jablonski S.A., Yen T.J., Yoda K., Robey R., Bates S.E., Sackett D.L. Inhibitors of histone deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell Cycle 2005, 4:717-726.
11. Blackwell L., Norris J., Suto C.M., Janzen W.P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci 2008, 82:1050-1058.
12. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
13. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26(49):5420-5432.
14. Emanuele S., Lauricella M., Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications. Int J Oncol 2008, 33:637-646.
15. Xu W., Ngo L., Perez G., Dokmanovic M., Marks P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 2006, 103:15540-15545.
16. Rosato R.R., Almenara J.A., Dai Y., Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003, 2:1273-1284.
17. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001, 98:10833-10838.
18. Parmigiani R.B., Xu W.S., Venta-Perez G., Erdjument-Bromage H., Yaneva M., Tempst P., Marks P.A. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A 2008, 105:9333-9338.
19. Ahn M.Y., Jung J.H., Na Y.J., Kim H.S. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008, 108:27-33.
20. Ahn M.Y., Chung H.Y., Choi W.S., Lee B.M., Yoon S., Kim H.S. Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4. Int J Oncol 2010, 36:125-131.
21. Marks P.A., Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007, 25:84-90.
22. Abbas A., Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008, 3:300-309.
23. Weichert W., Röske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M., Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008, 98:604-610.
24. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
25. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23:3923-3931.
26. Martínez-Iglesias O., Ruiz-Llorente L., Sánchez-Martínez R., García L., Zambrano A., Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 2008, 10:395-398.
27. Sonnemann J., Bumbul B., Beck J.F. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther 2007, 6:2976-2984.
28. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000, 60:5165-5170.
29. Fronsdal K., Saatcioglu F. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells. Prostate 2005, 62:299-306.
30. Qu Z., MacLellan W.R., Weiss J.N. Dynamics of the cell cycle: checkpoints, sizers, and timers. Biophys J 2003, 85:3600-3611.
31. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 2004, 91:223-231.
32. kip1 deficiency impairs G2/M arrest in response to DNA damage, leading to an increase in genetic instability. Mol Cell Biol 2008, 28:258-268.
33. Degregori J., Leone G., Ohtani K., Miron A., Nevins J.R. E2F-1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev 1995, 9:2873-2887.
34. Sherr C.J. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians 1995, 107:181-186.
35. Hitomi M., Stacey D.W. Cyclin D1 production in cycling cells depends on ras in a cell-cycle-specific manner. Curr Biol 1999, 9:1075-1084.
36. Guo Y., Stacey D.W., Hitomi M. Post-transcriptional regulation of cyclin D1 expression during G2 phase. Oncogene 2002, 21:7545-7556.
37. Sowa Y., Orita T., Minamikawa S., Nakano K., Mizuno T., Nomura H., Sakai T. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997, 241:142-150.
38. Kamitani H., Taniura S., Watanabe K., Sakamoto M., Watanabe T., Eling T. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. Neuro Oncol 2002, 4:95-101.
39. Liu P.Y., Chan J.Y., Lin H.C. Modulation of the cyclin-dependent kinase inhibitor p21 (WAF1/Cip1) gene by Zac1through the antagonistic regulators p53 and histone deacetylase 1in HeLa Cells. Mol Cancer Res 2008, 6:1204-1214.
40. Wilson A.J., Byun D.S., Nasser S., Murray L.B., Ayyanar K., Arango D., Figueroa M., Melnick A., Kao G.D., Augenlicht L.H., Mariadason J.M. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell 2008, 19:4062-4075.
41. ZhaoY, Lu S., Wu L., Chai G., Wang H., Chen Y., Sun J., Yu Y., Zhou W., Zheng Q., Wu M., Otterson G.A., Zhu W.G. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21 (Waf1/Cip1). Mol Cell Biol 2006, 26:2782-2790.
42. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
43. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1:287-299.
44. Culig Z., Klocker H., Eberle J., Kaspar F., Hobisch A., Cronauer M.V., Bartsch G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate 1993, 22:11-22.
45. Buchanan G., Craft P.S., Yang M., Cheong A., Prescott J., Jia L., Coetzee G.A., Tilley W.D. PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate 2004, 60:352-366.
46. Lu S., Liu M., Epner D.E., Tsai S.Y., Tsai M.J. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999, 13:376-384.
47. Alimirah F., Chen J., Basrawala Z., Xin H., Choubey D. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: implications for the androgen receptor functions and regulation. FEBS Lett 2006, 580:2294-3000.